Maggie will travel to Fort Collins for the surgery, and veterinarians will also take a biopsy to confirm that the cancer is osteosarcoma. If it is, Maggie's case will become part of a clinical trial at Colorado State University that is exploring the use of immunotherapy in dogs with this type of cancer.
One Cure is a project led by the Flint Animal Cancer Center at Colorado State University. The One Cure program is founded on the principle that cancer affects all creatures and that treatment breakthroughs come through collaboration between scientists and doctors working with people and animals.
"This is a real honor to carry the One Cure paint scheme and spread the word on all the good work Colorado State's Flint Animal Cancer Center is doing," Clint Bowyer said.
The Colorado State University Stuart Chair in Oncology passed from Dr. Stephen Withrow, founding director of CSU’s Flint Animal Cancer Center, to Dr. Susan Lana, oncology professor and clinical oncology service chief at the James L. Voss Veterinary Teaching Hospital.
With their genetic similarities, doctors say cancer treatments developed for dogs could help humans.
"The genetic difference between humans and dogs is quite small," said Dr. Rodney Page, professor of medical oncology and director of the Flint Animal Cancer Center. "Humans and dogs are 95 percent identical genetically — and the diseases that affect humans including breast cancer, prostate cancer, and melanoma are almost identical."
Rahal Letterman Lanigan Racing announced today that One Cure, an initiative from the Flint Animal Cancer Center at Colorado State University, will be the primary sponsor of the No. 15 Verizon IndyCar Series entry of Graham Rahal at ISM Raceway on April 7 and Portland International Raceway, Sept. 2.
A $6.4 million grant from the Open Philanthropy Project will support a clinical trial at Colorado State University's Flint Animal Cancer Center of a vaccine to prevent any type of cancer in dogs.
Terry Opgenorth, who holds a doctorate in physiology, built a 12-member team and went through the steps of taking an idea to market, launching the first conditionally approved drug for canine lymphoma, Tanovea-CA1.
“Schedule an appointment with a board-certified veterinary oncologist, since it’s our job to know about the all potential treatment options — conventional and new, clinical trials, etc.” -Dr. Barbara Biller